Abstract: A fragrance dispenser can comprise a housing having a socket portion and defining a receptacle configured to receive a bottle having a fragrance-producing liquid therein and a wick extending therefrom. A heater can be disposed proximate to the receptacle so that, when the bottle is received within the receptacle, the heater is disposed proximate to the wick. A controller can be configured to deliver electrical voltage (e.g., pulse-width-modulated voltage) to the heater. A user input device can be in communication with the controller. The controller receives an input from the user input device that is indicative of a selected heat profile of a plurality of heat profiles, and the controller controls the power output of the heater in accordance with the selected heat profile.

Abstract: Containers are provided herein for facilitating freezing, thawing, and/or storage of products that may be perishable, such as pharmaceuticals. The containers can include shells that enclose the product, and that include apertures permitting flow of a fluid through the containers' internal volume. The temperature of the fluid can be selected so as to freeze or thaw the product. The container optionally can include pressure building members that control the flow of the fluid through the containers' inner volume, e.g., increase the fluid flow rate and thus increase the rate with which the fluid is frozen or thawed.

Abstract: A gateway includes memory configured to store computer-readable program code; and processing circuitry configured to access the memory and execute the computer-readable program code. The gateway is connected or connectable to a low-power wide area (LPWA) network. The gateway is caused to transmit a common timing reference at a constant interval that delineates an epoch including timeslots assignable to network nodes and a free-for-all interval. The gateway is also caused to join a network node to the LPWA network based on the common timing reference and is further caused to receive a join message including a measure of received signal strength or quality of the common timing reference at the network node. The gateway is also caused to assign one or more timeslots within the epoch, a frequency, a channel, or a modulation to the network node based on the measure of received signal strength or other quality.

Abstract: Implementations described and claimed herein provide systems, methods and computer-readable media with instructions for detecting anomalies in computer network traffic online, real-time, historical, forensic, and/or playback mode. The implementations can include monitoring network traffic metadata, parsing the metadata, constructing a multi-partite graph of nodes and edges based on a long-term incremental signal transformation or a short-term concurrent snapshot, and generating streaming analytics based on the multi-partite graph representing a likelihood that network traffic associated with a specified network component is infected with malware.

Abstract: A fragrance dispenser can comprise a housing having a socket portion and defining a receptacle configured to receive a bottle having a fragrance-producing liquid therein and a wick extending therefrom. A heater can be disposed proximate to the receptacle so that, when the bottle is received within the receptacle, the heater is disposed proximate to the wick. A controller can be configured to deliver electrical voltage (e.g., pulse-width-modulated voltage) to the heater. A user input device can be in communication with the controller.

Abstract: A gateway includes memory configured to store computer-readable program code; and processing circuitry configured to access the memory and execute the computer-readable program code. The gateway is connected or connectable to a low-power wide area (LPWA) network. The gateway is caused to transmit a common timing reference at a constant interval that delineates an epoch including timeslots assignable to network nodes and a free-for-all interval. The gateway is also caused to join a network node to the LPWA network based on the common timing reference and is further caused to receive a join message including a measure of received signal strength or quality of the common timing reference at the network node. The gateway is also caused to assign one or more timeslots within the epoch, a frequency, a channel, or a modulation to the network node based on the measure of received signal strength or other quality.

Abstract: A system for manipulating and transporting items of various sizes and shapes comprising a carry-all handle having affixed thereto at least two hook and hook-loop fastened strips of length A, and a plurality of additional hook and loop fastener strips of various lengths which can be connected to the strips of length A so that the carry-all handle can be attached to and manipulate items of various sizes and shapes.

Abstract: A system for manipulating and transporting items of various sizes and shapes comprising a carry-all handle having affixed thereto at least two hook and hook-loop fastened strips of length A, and a plurality of additional hook and loop fastener strips of various lengths which can be connected to the strips of length A so that the carry-all handle can be attached to and manipulate items of various sizes and shapes.

Abstract: A freezing and thawing unit for small amounts of biopharmaceuticals and biologics. The freezing and thawing unit is reduced in scale, as compared to a corresponding commercial or large-scale process. The freezing and thawing unit can be used for testing, preservation and/or processing of small quantities of biopharmaceuticals and biologics.

Abstract: Disclosed are methods for thawing frozen biopharmaceutical solutions including providing a container that contains a biopharmaceutical solution, at least a portion of the biopharmaceutical solution being frozen, providing an oscillatory driver coupled to the biopharmaceutical solution; providing a heat flux into the biopharmaceutical solution; and inducing oscillatory motion of the biopharmaceutical solution via oscillatory motion of the oscillatory driver to accelerate thawing, compared to motionless thawing, of the portion of the biopharmaceutical solution that is frozen. Also disclosed are devices for thawing frozen biopharmaceutical solutions.

Abstract: The present invention provides a system for freezing, thawing, and storing biopharmaceutical materials which includes a flexible container, a conduit, and a temperature control unit. The flexible container is adapted to receive a biopharmaceutical material therein for freezing, thawing, and storing. The container is formed of a first substantially flat sheet of flexible material joined together by a seam with a second substantially flat sheet of flexible material so as to lie substantially flat when empty. The container fully encloses an interior portion for receiving the biopharmaceutical material. Also, the container is configured to form a three dimensional shape when filled with the biopharmaceutical material, wherein the three dimensional shape has a first side and a second side opposite the first side. The conduit is connected to the flexible container with the outside of the container being in fluid communication with the interior portion via the conduit.

Abstract: Disclosed is a biopharmaceutical product cryopreservation system, for cryopreserving a biopharmaceutical product that includes a cryopreservation compartment; a cryopreservation fluid located within the cryopreservation compartment; and a biopharmaceutical product cryopreservation vial located within the cryopreservation compartment and surrounded by the cryopreservation fluid, and the biopharmaceutical product cryopreservation vial including a body that includes an oblong cross-section defining proximal and distal ends of the body, and at least one nucleating structure, coupled to a distal end of the body, and the body including a cryogenically stable material that is compatible with biopharmaceutical products. Also disclosed are cryopreservation vials and methods of cryopreserving biopharmaceutical products.

Abstract: A freezing and thawing unit for small amounts of biopharmaceuticals and biologics. The freezing and thawing unit is reduced in scale, as compared to a corresponding commercial or large-scale process. The freezing and thawing unit can be used for testing, preservation and/or processing of small quantities of biopharmaceuticals and biologics.

Abstract: The present invention provides a system for freezing, thawing, and storing biopharmaceutical materials which includes a flexible container, a conduit, and a temperature control unit. The flexible container is adapted to receive a biopharmaceutical material therein for freezing, thawing, and storing. The container is formed of a first substantially flat sheet of flexible material joined together by a seam with a second substantially flat sheet of flexible material so as to lie substantially flat when empty. The container fully encloses an interior portion for receiving the biopharmaceutical material. Also, the container is configured to form a three dimensional shape when filled with the biopharmaceutical material, wherein the three dimensional shape has a first side and a second side opposite the first side. The conduit is connected to the flexible container with the outside of the container being in fluid communication with the interior portion via the conduit.

Abstract: The present invention provides a system for thawing, mixing and processing a biopharmaceutical material, which includes a moveable platform and a container for holding the biopharmaceutical material. The container is operably mounted on the platform to allow the container to be skewed relative to the platform. Further, the container may be tilted relative to the platform.

Abstract: The present invention provides a system for freezing, thawing, and storing biopharmaceutical materials which includes a flexible container, a conduit, and a temperature control unit. The flexible container is adapted to receive a biopharmaceutical material therein for freezing, thawing, and storing. The container is formed of a first substantially flat sheet of flexible material joined together by a seam with a second substantially flat sheet of flexible material so as to lie substantially flat when empty. The container fully encloses an interior portion for receiving the biopharmaceutical material. Also, the container is configured to form a three dimensional shape when filled with the biopharmaceutical material, wherein the three dimensional shape has a first side and a second side opposite the first side. The conduit is connected to the flexible container with the outside of the container being in fluid communication with the interior portion via the conduit.

Abstract: A biopharmaceutical material cryopreservation system is provided that includes a flexible sterile container comprising a biocompatible polymeric material. The flexible sterile container contains biopharmaceuticals materials for freezing and cryopreservation. A freezing system is thermally coupled to the biopharmaceutical materials via the flexible sterile container. The freezing system comprises a temperature sensor that monitors a temperature of the biopharmaceutical materials. Also, the freezing system comprises a feedback loop constructed to control a dendritic freezing front velocity, within the biopharmaceutical materials, in a range from approximately 5 millimeters per hour to approximately 250 millimeters per hour based on feedback information from the temperature sensor.

Abstract: A biopharmaceutical cryopreservation system includes a container having an outer surface area with the container being adapted to contain a biopharmaceutical material for freezing and thawing therein. The container may be received in a cryocooling enclosure having an interior cavity configured to receive it. The cryocooling enclosure includes at least one heat transfer surface configured to contact the outer surface area of the container when the cryocooling enclosure interior cavity receives the container. Also, a cryocooler is thermally coupled to the cryocooling enclosure and is configured to flow a fluid to the at least one heat transfer surface to control the temperature of the heat transfer surface and the biopharmaceutical material within the container. The fluid is isolated from contacting the container. Further, a temperature sensor is thermally coupled to the cryocooling enclosure, the at least one heat transfer surface, the fluid and/or the cryocooler.